Publicaciones en las que colabora con Álvaro Teijeira Sánchez (22)

2023

  1. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

    Science advances, Vol. 9, Núm. 33, pp. eadf6692

  2. Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8+ T cells eradicates peritoneal metastases in mouse models

    Oncoimmunology, Vol. 12, Núm. 1, pp. 2147317

  3. Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis

    Journal for immunotherapy of cancer, Vol. 11, Núm. 11

  4. Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity

    Cancer immunology research, Vol. 11, Núm. 2, pp. 184-198

  5. Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies

    EMBO Molecular Medicine, Vol. 15, Núm. 11

  6. Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists

    Molecular Therapy - Nucleic Acids, Vol. 33, pp. 668-682

  7. Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure

    Molecular Therapy - Nucleic Acids, Vol. 33, pp. 599-616

  8. Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic

    OncoImmunology, Vol. 12, Núm. 1

  9. Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma

    Cell Reports Medicine, Vol. 4, Núm. 4

  10. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy

    Cell Reports Medicine, Vol. 4, Núm. 3

2022

  1. A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα and IL-1β

    Cancer Discovery, Vol. 12, Núm. 9, pp. 2140-2157

  2. Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy

    Cancer research, Vol. 82, Núm. 23, pp. 4373-4385

  3. Novel strategies exploiting interleukin-12 in cancer immunotherapy

    Pharmacology and Therapeutics, Vol. 239

  4. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 3

  5. Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis

    OncoImmunology, Vol. 11, Núm. 1

  6. Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers

    Theranostics, Vol. 12, Núm. 3, pp. 1373-1387

2021

  1. Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 26

  2. Differential Interleukin-8 thresholds for chemotaxis and netosis in human neutrophils

    European Journal of Immunology, Vol. 51, Núm. 9, pp. 2274-2280

  3. IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy

    Clinical Cancer Research, Vol. 27, Núm. 9, pp. 2383-2393

  4. Mouse models of peritoneal carcinomatosis to develop clinical applications

    Cancers, Vol. 13, Núm. 5, pp. 1-11